News

Ligand Licenses VER250840 to Cumulus Oncology

Ligand Pharmaceuticals has announced the signing of a license agreement granting Cumulus Oncology exclusive worldwide rights to develop and commercialise VER250840, a novel, oral, selective, preclinical Chk1 Kinase Inhibitor discovered using Ligand’s Vernalis Design Platform (VDP). Under the terms of the agreement, Ligand will receive an upfront license fee, and...

Read more

Closed Loop Medicine Raises £2.1M Pre-Series A

GJE client Closed Loop Medicine raised £2.1M in venture capital funding. The raise for the Cambridge-based health tech start-up was from Longwall Ventures Partners amongst other investment groups. Closed Loop Medicine is a start-up that helps doctors and healthcare providers deliver personalised treatment regimens by combining proven drug treatments with...

Read more

Stays may be available for computer simulation inventions at the EPO

Following on from our article commenting on the recent referral to the Enlarged Board of Appeal (G 1/19) the EPO have published a further notice concerning the staying of proceedings. The notice indicates that the President of the EPO has decided that all proceedings before the EPO in which the...

Read more

The President of the EPO is determined to prevent patents issuing directed to plants obtained by essentially biological processes

In a notice published yesterday, the President of the EPO has decided to stay any examination or opposition proceedings at the EPO where the patent application or patent in question claims a plant or animal exclusively obtained by means of an essentially biological process. This decision has been taken to...

Read more

GJE recognised by Managing IP Stars 2019

We are delighted to have been listed as a leading firm in the 2019 edition of Managing IP. Every year, the publication independently researches practices in order to identify the world’s leading firms and individuals. The aspects assessed for the firm rankings include expertise, workload, market reputation/track record, outcomes achieved...

Read more